Literature DB >> 2434730

Mechanisms of malignant ascites production.

R N Garrison, R H Galloway, L S Heuser.   

Abstract

The accumulation of malignant ascites is determined primarily by the obstruction of diaphragmatic lymphatics with tumor inhibiting the outflow of peritoneal fluid. An abnormal increase in peritoneal fluid production has been shown to contribute to ascites formation by a marked neovascularization of the parietal peritoneum. Cell-free malignant ascitic fluid obtained from rats with intra-abdominal Walker 256 carcinoma when infused into the peritoneal cavities of normal animals causes an increase in edema formation and an increase in the permeability of protein from normal omental vessels. Protamine sulfate, a known inhibitor of angiogenesis when infused into the peritoneal cavity along with cell free malignant ascitic fluid, significantly reduces the leak of protein from the intravascular space when compared to ascites alone. Persistent permeability changes continue to exist even after the inhibition of vessel proliferation. These results indicate that angiogenesis is responsible for a major portion of the increase in permeability caused by malignant ascitic fluids. Other tumor-induced factors may be present which alter vascular permeability by other mechanisms which remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434730     DOI: 10.1016/0022-4804(87)90109-0

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  9 in total

1.  Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions.

Authors:  V Hird; J S Stewart; D Snook; B Dhokia; C Coulter; H E Lambert; W P Mason; W P Soutter; A A Epenetos
Journal:  Br J Cancer Suppl       Date:  1990-07

Review 2.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

3.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

Review 4.  Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Clin Pharmacol       Date:  2013-10-03

Review 5.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.

Authors:  Yuliya Klymenko; Oleg Kim; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2017-08-09       Impact factor: 6.639

6.  Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.

Authors:  Roni Oren; Yoseph Addadi; Lian Narunsky Haziza; Hagit Dafni; Ron Rotkopf; Gila Meir; Ami Fishman; Michal Neeman
Journal:  Int J Cancer       Date:  2016-06-20       Impact factor: 7.396

7.  Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Int J Womens Health       Date:  2012-08-03

8.  Modeling the effect of ascites-induced compression on ovarian cancer multicellular aggregates.

Authors:  Yuliya Klymenko; Rebecca B Wates; Holly Weiss-Bilka; Rachel Lombard; Yueying Liu; Leigh Campbell; Oleg Kim; Diane Wagner; Matthew J Ravosa; M Sharon Stack
Journal:  Dis Model Mech       Date:  2018-09-25       Impact factor: 5.758

Review 9.  Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.

Authors:  Yuliya Klymenko; Kenneth P Nephew
Journal:  Cancers (Basel)       Date:  2018-08-30       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.